DIPG-lysate clinical trials

Phase Ib, non-randomized, single-arm, open-label, single-center clinical trial to evaluate the safety of the first-in-human administration of the combination of dendritic cell (DC) immunization pulsed with tumor lysate and CAR-T cells targeting IL13Ra2 in patients with newly diagnosed diffuse intrinsic pontine glioma (DIPG)

This early-stage study is looking at a new combination treatment for children and young adults with a serious brain tumour called DIPG. It aims to check the safety of giving a special vaccine along with modified immune cells to fight the cancer before testing how well it works.